Skip to main content
. 2016 Oct 5;2016:3038164. doi: 10.1155/2016/3038164

Table 1.

Preclinical and experimental studies on PPAR agonists in neuroblastoma.

Drug/s Reference/s Year Target Study types Cell lines/animal model Effects
15-deoxy-PGJ2 [1116] 2001, 2003, 2004 PPAR-γ In vitro NB cell lines and primary cultures of cortical neurons Inhibition of growth and apoptosis induction, through PPAR-γ-dependent and PPAR-γ-independent effects.

GW1929 [11] 2001 PPAR-γ In vitro LA-N-5 Prodifferentiating effect and inhibition of proliferation.

Rosiglitazone and 15-deoxy-PGJ2 [12] 2004 PPAR-γ In vitro SH-SY5Y, SH-EP1, SK-N-AS, SK-N-FI, LA-N-5, SMS-KCNR, SK-N-DZ, and LA-N-1 Inhibition of cell growth with different sensitivity related to the cell phenotype.

Ciglitazone and 15-deoxy-PGJ2 [13] 2004 PPAR-γ In vitro SK-N-AS, IMR-32, SK-N-SH, and ND-7 Overexpression of Rb protein and inhibition of PPAR-γ activity, reducing NB cell growth.

Ciglitazone, pioglitazone, troglitazone, and rosiglitazone [17] 2005 PPAR-γ In vitro Kelly, LA-N-1, LA-N-5, LS, IMR-32, SK-N-SH, and SH-SY5Y Inhibition of cell proliferation and viability in a dose-dependent manner.

Rosiglitazone [18] 2010 PPAR-γ In vivo SK-N-SH xenograft NB mouse model Inhibition of tumor growth.

Troglitazone [19] 2002 PPAR-γ In vitro NB-1 cell line Increase of PPAR-γ-dependent apoptosis.

Troglitazone [20] 2006 PPAR-γ In vitro SHEP NB cell line Increase of PPAR-γ-dependent apoptosis.

Rosiglitazone [21, 22] 2006, 2007 PPAR-γ In vitro SH-SY5Y cell line Antiapoptotic effects of rosiglitazone which protected NB cells subjected to MPP+-induced mitochondrial injury reducing ROS production.

Rosiglitazone [23] 2006 PPAR-γ In vitro SK-N-AS and SH-SY5Y cell lines Inhibition of cell adhesion, invasiveness, and proapoptotic effects.

Rosiglitazone [24] 2010 PPAR-γ In vivo SK-N-AS xenograft NB mouse model Significant decrease of tumor growth (−70%) as compared to control mice.

Rosiglitazone [25] 2008 PPAR-γ In vitro Rat primary cortical neurons Induction of cell differentiation, increasing dendritic spine density.

Pioglitazone and rosiglitazone [26] 2011 PPAR-γ Both in vitro and in vivo Adult male Wistar rats Induction of proliferation, differentiation, and migration of neural stem cells in vitro and in vivo.

Pioglitazone [27] 2009 PPAR-γ In vitro SH-SY5Y cell line Induction of differentiation and neurite outgrowth, promoting differentiation and outgrowth of cell processes.

Rosiglitazone [28] 2014 PPAR-γ In vitro Mouse NB Neuro 2a (N2A) cell line Stimulation of neurite outgrowth and significant increase of the population of neurite-bearing cells, via PPAR-γ pathway.

Oleic acid or GW0742 [29] 2007 PPAR-β/δ In vitro SH-NH-5YSY cell line Induction of G1 cell cycle arrest, reduction of cell migration and invasiveness, and an increase of neuronal differentiation.